Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CBL-514

Phase 3Small molecule

CCaliway Biopharmaceuticals Co., Ltd.

1

Indications

12

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Subcutaneous FatRecruiting

Subcutaneous FatPhase 3

Recruiting

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Subcutaneous Fat

NCT07140939

Clinical

Trials by Indication[1]

Subcutaneous Fat6 trials

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT04698642·43 enrolled

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT05736107·107 enrolled

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT04575467·25 enrolled

Show 3 more trials

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 1·NCT04699669·40 enrolled

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT04897412·75 enrolled

A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.

Recruiting·CCaliway Biopharmaceuticals Co., Ltd.·Phase 3·NCT07140939·320 enrolled

Cellulite2 trials

A Phase 2a, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of CBL-514 Injection for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite (Stage 1)

Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT05632926·12 enrolled

A Phase 2a, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of CBL-514 Injection for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite (Stage 2)

Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT05836779·23 enrolled

Efficacy and Safety1 trial

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT06005441·173 enrolled

Lipoma1 trial

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT05387733·12 enrolled

Dercum's Disease1 trial

A Single-Blind, Placebo-Control, Randomized Phase 2 Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT06303570·19 enrolled

1 more indication

Unspecified1 trial

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Completed·CCaliway Biopharmaceuticals Co., Ltd.·Phase 2·NCT05234736·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for CBL-514. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CBL-514 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CBL-514. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Caliway Biopharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCaliway Biopharmaceuticals Co., Ltd.

Related News